1[1]Iynch HT, Casey MJ, Lunch J, et al. Genetics and ovarian carcinoma. Semin Oncol 1998 Jun;25(3):265～80
2[2]Aunoble B, Sanches R, Didier E, et al. Major oncogene and tumor suppresser gene involved in epiehelial ovarian cancer. Int J Oncol 2000 Mar; 16(3):567～76
3[3]Morita K, One Y, Fukui H, et el. Incidence of P53 and K-ras alterations in ovarian mncinous and tumors.Pathol Int 2000 Mar;50(3):219～23
4[4]Garrett AP, Lee KR, Colitti CR, et al. K-ras mutation may be an early event in mucinòus ovarian tumorigenesis.Int J Gynecol Pathol 2001 Jul;20(3):244～51
5[5]Ross JS, Yang F, Kallakury BV, et al. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am J Clin Pathol 1999 111:311～16
6[6]Felip E, Del Campo JM, Rubio D, et al. Overexpression of c-erbB2 in epithelial ovarian cancer. Prognostic Value and relationship with response to chemotherapy. Cancer 1995 75:2147～52
7[7]Tashiro H, Miyazaki K, Okamura H, et al. c-myc over-expression in human primary ovarian tumors: its relevance to tumor progression, Int J Cancer 1992,50:828～33
8[8]Baker VV, Borst MP, Dixon D, et al. C-myc amplification in ovarian cancer. Gynecol Oncol, 1990,38: 340～5
9[9]Beale PJ, Rngers P, Boxall F, et al. Bcl-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer 2000;82(2):436～40.
10[10]Kassim SK,Ali HS, Sallam MM, et al.Increased Bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer.Clin Biochem 1999 Jul;32(5):338～8
